Safety Study

The 12-Month Laboratory Safety Study1 demonstrated capromorelin was well-tolerated in dogs at daily doses up to 40 mg/kg (17.5x labeled dose) for 12 months.


Event, % of Dogs*Placebo (n=8)0.3 mg/kg (n=8)7 mg/kg (n=8)40 mg/kg (n=8)
Emesis75% (1–3)63% (1–2)63% (1–4)75% (1–6)
Loose stools100% (1–41)100% (5–32)100% (2–220)100% (1-46)
Excessive salivation13% (4)088% (1–104)100% (34–354)
*Results in parentheses are reported as the range of days on which the adverse events were observed.


Study Design

  • Beagle dogs (n=32) received either oral placebo or 0.3, 7, or 40 mg/kg capromorelin oral solution administered once-daily for 12 consecutive months
  • Safety was evaluated by physical examinations, including electrocardiogram (ECG), ophthalmic examinations and comprehensive clinical pathology


Capromorelin was well-tolerated in dogs at daily doses up to 40 mg/kg for 12 months. The minimal toxicity observed across multiple body systems when capromorelin was administered at doses substantially higher than the labeled dose over an extended period of time supports the wide safety margin for the use of capromorelin in dogs.


1Zollers B, Huebner M, Armintrout G, Rausch-Derra LC, Rhodes L. Evaluation of the safety in dogs of long-term, daily oral administration of capromorelin (ENTYCE®), a novel drug for stimulation of appetite. J Vet Pharmacol Ther. 2016 Sep 25. Doi: 10.1111/jvp.12358.

Clinical References

Your convenient one-stop source for viewing and downloading important information.

Learn more >

In-Clinic Tools

Introducing ENTYCE to your clinic as a therapeutic solution specifically designed to stimulate appetite in dogs.

Learn more >


Keep current on all the latest Aratana news, upcoming conferences and other timely information.

Learn more >

IMPORTANT SAFETY INFORMATION: ENTYCE® (capromorelin oral solution) is for use in dogs only. Do not use in breeding, pregnant or lactating dogs. Use with caution in dogs with hepatic dysfunction or renal insufficiency. Adverse reactions in dogs may include diarrhea, vomiting, polydipsia, and hypersalivation. Should not be used in dogs that have a hypersensitivity to capromorelin. Please see the full Prescribing Information for more detail.

ENTYCE is Now Available

Other therapeutics from Aratana

Nocita Logo

NOCITA® (bupivacaine liposome injectable suspension)

provides post-operative pain relief for cranial cruciate ligament surgery for up to 72 hours.

Now you can be sure dogs are getting the post-surgical pain relief they need even after they leave your clinic.

IMPORTANT SAFETY INFORMATION: NOCITA® (bupivacaine liposome injectable suspension) is for use in dogs only. Do not use in dogs younger than 5 months of age, dogs used for breeding, or in pregnant or lactating dogs. Do not administer by intravenous or intra-arterial injection. Adverse reactions in dogs may include discharge from incision, incisional inflammation and vomiting. Avoid concurrent use with bupivacaine HCl, lidocaine or other amide local anesthetics. Please see the full Prescribing Information for more detail.